{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:36:53Z","timestamp":1787071013574,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"\n Background:<\/jats:title>\n Patients with clinically localised prostate cancer (CaP) have a potentially curable disease. However, there are gaps in the quality of care these patients receive in Nigeria. Granular clinical data are needed to design interventions for quality improvement.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n This study aimed to describe guideline concordance of cancer management and its association with patient outcomes.<\/jats:p>\n <\/jats:sec>\n \n Subjects and Methods:<\/jats:title>\n A 3-year retrospective study of all patients with T1-T3a, N0, M0 CaP at three tertiary hospitals in Nigeria was conducted. Data on clinicopathologic characteristics, D\u2019\u00c1mico risk group, TNM staging, treatment practices, post-treatment PSA and survival were collected. Concordance with the 2022 European Association of Urology guideline was assessed. Primary endpoints were guideline concordance of staging and treatment, and associations between concordance and outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n This study included 110 patients with mean age of 68 years. Sixty-seven patients (60.9%) were high-risk, 34 (30.9%) were intermediate-risk and 9 (82%) were low-risk. Most patients were staged with abdominopelvic ultrasound (65%,\n n<\/jats:italic>\n = 71). Guideline-concordant magnetic resonance imaging for T-staging was significantly higher in low-risk (44%,\n n<\/jats:italic>\n = 4) than in high-risk (12%,\n n<\/jats:italic>\n = 8) patients (\n P<\/jats:italic>\n = 0.041). Guideline-concordant axial imaging for N and M staging was used in 11% (\n n<\/jats:italic>\n = 7) of high-risk patients. In the overall cohort, 17 patients (15%) received guideline-concordant definitive treatment with either radical prostatectomy (\n n<\/jats:italic>\n = 8; 9%) or radiotherapy (\n n<\/jats:italic>\n = 9; 5%), whereas 52 patients (56%) received non-concordant androgen deprivation therapy (ADT) alone and 43 received no treatment. Median time to biochemical recurrence was not significantly different between those who received surgery (18 months), radiation therapy (median not obtained) or ADT alone (11 months) (log-rank\n P<\/jats:italic>\n = 0.103). After a median follow-up of 36 months, median overall survival was similar for guideline-concordant and non-concordant treatment groups (37 and 34 months, respectively; log-rank\n P<\/jats:italic>\n = 0.540).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n CaP staging was suboptimal across all risk groups. Only a minority of patients received radical treatment for this potentially curable disease. Our results will inform the development of tailored multifaceted interventions to improve the quality of care.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/npmj.npmj_50_25","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T06:00:19Z","timestamp":1754028019000},"page":"211-213","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Management of Clinically Localised Prostate Cancer: Guideline Concordance and Clinical Outcomes from Tertiary Institutions in Nigeria"],"prefix":"10.4103","volume":"32","author":[{"given":"Christian Agbo","family":"Agbo","sequence":"first","affiliation":[{"name":"Department of Surgery, Benue State University, Makurdi\/Federal University Teaching Hospital, Lafia, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musliu Adetola","family":"Tolani","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ahmadu Bello University, Zaria, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufus Wale","family":"Ojewola","sequence":"additional","affiliation":[{"name":"Department of Surgery, Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/aam.aam_101_20","article-title":"Prostate cancer characteristics: A descriptive analysis of clinical features at presentation in the last decade in a black African community","volume":"21","author":"Ugwumba","year":"2022","journal-title":"Ann Afr Med"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0272989X16662841","article-title":"Physician recommendations trump patient preferences in prostate cancer treatment decisions","volume":"37","author":"Scherr","year":"2017","journal-title":"Med Decis Making"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pros.23923","article-title":"Disparities in prostate cancer incidence and mortality rates: Solvable or not?","volume":"80","author":"Badal","year":"2020","journal-title":"Prostate"},{"key":"R5-20260421","first-page":"1138","article-title":"Usefulness of prostate specific antigen density in prostate cancer detection among men with PSA of 4-10 ng\/ml","volume":"10","author":"Agbo","year":"2020","journal-title":"Ann Med Health Sci Res"},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/1596-3519.68353","article-title":"An overview of cancer of the prostate diagnosis and management in Nigeria: The experience in a Nigerian tertiary hospital","volume":"9","author":"Ajape","year":"2010","journal-title":"Ann Afr Med"},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/jwas.jwas_274_22","article-title":"Correlation between serum prostate-specific antigen and testosterone following bilateral total orchidectomy for patients with advanced prostate cancer in Jos, Nigeria","volume":"13","author":"Osunaiye","year":"2023","journal-title":"J West Afr Coll Surg"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"129","DOI":"10.11604\/pamj.2013.15.129.2489","article-title":"Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination","volume":"15","author":"Ikuerowo","year":"2013","journal-title":"Pan Afr Med J"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.urology.2010.03.020","article-title":"Burden of prostate cancer in Southwestern Nigeria","volume":"76","author":"Badmus","year":"2010","journal-title":"Urology"},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ypmed.2004.01.005","article-title":"Prostate-specific antigen test use reported in the 2000 National Health Interview Survey","volume":"38","author":"Ross","year":"2004","journal-title":"Prev Med"},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"e181172","DOI":"10.1001\/jamanetworkopen.2018.1172","article-title":"Association between guideline-discordant prostate cancer imaging rates and health care service among veterans and medicare recipients","volume":"1","author":"Makarov","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijrobp.2013.11.004","article-title":"Receipt of guideline-concordant treatment in elderly prostate cancer patients","volume":"88","author":"Chen","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"846.e17","DOI":"10.1016\/j.urolonc.2020.07.008","article-title":"Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: An analysis from the multi-institutional PURC cohort","volume":"38","author":"Talwar","year":"2020","journal-title":"Urol Oncol"},{"key":"R14-20260421","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"}],"container-title":["Nigerian Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_50_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:21Z","timestamp":1787067621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_50_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/npmj.npmj_50_25","relation":{},"ISSN":["1117-1936","2468-6875"],"issn-type":[{"value":"1117-1936","type":"print"},{"value":"2468-6875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-02-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}